Long-term Outcomes of ADEM-like and Tumefactive Presentations of CNS Demyelination: a Case-comparison Analysis

Overview

Journal J Neurol

Specialty Neurology

Date 2024 Jun 11

PMID 38861035

Authors

Simon V Arnett

Kerri Prain

Sudarshini Ramanathan

Sandeep Bhuta

Fabienne Brilot

Simon A Broadley

Affiliations

Soon will be listed here.

Abstract

A minority of initial multiple sclerosis (MS) presentations clinically or radiologically resemble other central nervous system (CNS) pathologies, acute disseminated encephalomyelitis (ADEM) or tumefactive demyelination (atypical demyelination presentations). With the aim of better defining the long-term outcomes of this group we have performed a retrospective cohort comparison of atypical demyelination versus 'typical' MS presentations. Twenty-seven cases with atypical presentations (both first and subsequent demyelinating events) were identified and compared with typical MS cases. Disease features analysed included relapse rates, disability severity, whole brain and lesion volumes, lesion number and distribution. Atypical cases represented 3.9% of all MS cases. There was considerable overlap in the magnetic resonance imaging (MRI) features of ADEM-like and tumefactive demyelination cases. ADEM-like cases tended to be younger but not significantly so. Atypical cases showed a trend towards higher peak expanded disability severity score (EDSS) score at the time of their atypical presentation. Motor, cranial nerve, cerebellar, cerebral and multifocal presentations were all more common in atypical cases, and less likely to present with optic neuritis. Cerebrospinal fluid (CSF) white cell counts were higher in atypical cases (p = 0.002). One atypical case was associated with peripheral blood myelin oligodendrocyte glycoprotein (MOG) antibodies, but subsequent clinical and radiological course was in keeping with MS. There was no difference in long-term clinical outcomes including annualised relapse rates (ARR), brain volume, lesion numbers or lesion distributions. Atypical demyelination cases were more likely to receive high potency disease modifying therapy early in the course of their illness. Despite the severity of initial illness, our cohort analysis suggests that atypical demyelination presentations do not confer a higher risk of long-term adverse outcomes.

References

Gajofatto A, Calabrese M, Benedetti M, Monaco S . Clinical, MRI, and CSF markers of disability progression in multiple sclerosis. Dis Markers. 2013; 35(6):687-99. PMC: 3842089. DOI: 10.1155/2013/484959. View

McDonald W, Compston A, Edan G, Goodkin D, Hartung H, Lublin F . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50(1):121-7. DOI: 10.1002/ana.1032. View

Eckstein C, Saidha S, Levy M . A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis. J Neurol. 2011; 259(5):801-16. DOI: 10.1007/s00415-011-6240-5. View

Pohl D, Alper G, Van Haren K, Kornberg A, Lucchinetti C, Tenembaum S . Acute disseminated encephalomyelitis: Updates on an inflammatory CNS syndrome. Neurology. 2016; 87(9 Suppl 2):S38-45. DOI: 10.1212/WNL.0000000000002825. View

Karussis D . The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J Autoimmun. 2014; 48-49:134-42. DOI: 10.1016/j.jaut.2014.01.022. View

Fereidan-Esfahani M, Decker P, Weigand S, Lopez Chiriboga A, Flanagan E, Tillema J . Defining the natural history of tumefactive demyelination: A retrospective cohort of 257 patients. Ann Clin Transl Neurol. 2023; 10(9):1544-1555. PMC: 10502639. DOI: 10.1002/acn3.51844. View

Algahtani H, Shirah B, Alassiri A . Tumefactive demyelinating lesions: A comprehensive review. Mult Scler Relat Disord. 2017; 14:72-79. DOI: 10.1016/j.msard.2017.04.003. View

Lucchinetti C, Gavrilova R, Metz I, Parisi J, Scheithauer B, Weigand S . Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain. 2008; 131(Pt 7):1759-75. PMC: 2442427. DOI: 10.1093/brain/awn098. View

Frederick M, Cameron M . Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders. Curr Neurol Neurosci Rep. 2016; 16(3):26. DOI: 10.1007/s11910-016-0626-9. View

10.

Sanchez P, Chan F, Hardy T . Tumefactive demyelination: updated perspectives on diagnosis and management. Expert Rev Neurother. 2021; 21(9):1005-1017. DOI: 10.1080/14737175.2021.1971077. View

11.

Krupp L, Tardieu M, Amato M, Banwell B, Chitnis T, Dale R . International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler. 2013; 19(10):1261-7. DOI: 10.1177/1352458513484547. View

12.

Codjia P, Ayrignac X, Carra-Dalliere C, Cohen M, Charif M, Lippi A . Multiple sclerosis with atypical MRI presentation: Results of a nationwide multicenter study in 57 consecutive cases. Mult Scler Relat Disord. 2018; 28:109-116. DOI: 10.1016/j.msard.2018.12.022. View

13.

De Seze J, Debouverie M, Zephir H, Lebrun C, Blanc F, Bourg V . Acute fulminant demyelinating disease: a descriptive study of 60 patients. Arch Neurol. 2007; 64(10):1426-32. DOI: 10.1001/archneur.64.10.1426. View

14.

Zaheer K, Ajmeri A, Singh M, Suliman M, Teka S . Tumefactive Multiple Sclerosis, A Rare Variant Presenting as Multiple Ring-enhancing Lesions in an Immunocompetent Patient: A Case Report. Cureus. 2019; 10(12):e3738. PMC: 6384036. DOI: 10.7759/cureus.3738. View

15.

Lin X, Yu W, Liauw L, Chander R, Soon W, Lee H . Clinicoradiologic features distinguish tumefactive multiple sclerosis from CNS neoplasms. Neurol Clin Pract. 2018; 7(1):53-64. PMC: 5964866. DOI: 10.1212/CPJ.0000000000000319. View

16.

Uehara T, Beck G, Baba K, Mihara M, Okuno T, Sumi H . Tumefactive brain lesion with rapid cavity formation associated with anti-aquaporin-4 antibody. Neurol Neuroimmunol Neuroinflamm. 2016; 3(3):e230. PMC: 4841638. DOI: 10.1212/NXI.0000000000000230. View

17.

Katsuse K, Kurihara M, Sugiyama Y, Kodama S, Takahashi M, Momose T . Aphasic status epilepticus preceding tumefactive left hemisphere lesion in anti-MOG antibody associated disease. Mult Scler Relat Disord. 2018; 27:91-94. DOI: 10.1016/j.msard.2018.10.012. View

18.

Balloy G, Pelletier J, Suchet L, Lebrun C, Cohen M, Vermersch P . Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients. J Neurol. 2018; 265(10):2251-2259. DOI: 10.1007/s00415-018-8984-7. View

19.

Liao M, Huang C, Lyu R, Chen C, Chang H, Chu C . Acute disseminated encephalomyelitis that meets modified McDonald criteria for dissemination in space is associated with a high probability of conversion to multiple sclerosis in Taiwanese patients. Eur J Neurol. 2010; 18(2):252-259. DOI: 10.1111/j.1468-1331.2010.03114.x. View

20.

Prain K, Woodhall M, Vincent A, Ramanathan S, Barnett M, Bundell C . AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD. Front Neurol. 2019; 10:1028. PMC: 6787171. DOI: 10.3389/fneur.2019.01028. View